Type 2 Diabetes Clinical Trial
Official title:
Study on the Feasibility and Treatment Experience of Community Doctors in Shenzhen Guided by Specialists to Use Basic Insulin in the Treatment of Adult Type 2 Diabetes Mellitus
At present, one of the reasons for the low blood sugar control rate in China is related to the late use of basic insulin and insufficient dose adjustment. If the community hospital can actively treat the diabetic patients who need to use insulin and adjust the dose in time, it will certainly improve the blood sugar control rate. However, at present, community doctors basically do not take the initiative to start insulin treatment, but only passively use insulin that has been prescribed by specialists, and there is a lack of ability to adjust the dose of insulin and treatment inertia. Therefore, it is very necessary for community doctors to receive guidance from endocrine specialists to improve their ability to use insulin. This study intends to carry out a study of endocrine specialists guiding community doctors to use basic insulin in the treatment of adult type 2 diabetes in Shenzhen Community Hospital. Through this study to understand whether the effectiveness and safety of community doctors actively using basic insulin therapy under the guidance of specialists can reach the level of specialists.
The study consists of two parts: the screening period and the treatment follow-up period.
1. Screening period (day 0): patients were screened according to the inclusion and
exclusion criteria, and informed consent was completed.
2. Treatment follow-up period (day 1-day 90): Day 1: (1)all patients in the group received
diet and exercise education;(2)Collect patients' basic data (name, sex, age, height,
weight, waist circumference, hip circumference, etc.), detect plasma FBG and HbA1c (sent
to the central laboratory for testing);(3)Initial treatment: On the basis of the
original oral medicine, the patient will initial basic insulin. The initial dose of
basic insulin is 0.2U/kg/d.
Day 2-Day 89:
1. Community patient group:The community doctor adjusts the dosage of insulin daily
according to the patient's FBG: the dose is titrated by increments of 0.07U/kg daily
until the fasting blood glucose (FBG)≤7 mmol / L, and if the FBG≤ 3.9mmol/L, the
0.07U/kg is reduced. Inpatient group:Endocrinologists in the in-patient department use
the same basic insulin dose adjustment regimen to treat patients.
2. It can be discontinued when the basic insulin is reduced to 8U and the fasting blood
glucose reaches the standard for 3 days.
Day 90:Patients were re-examined the plasma FBG and HbA1c (sent to the central laboratory for
testing), and community doctors filled in the treatment experience questionnaire.
Follow-up requirements: Patients use the complimentary blood glucose meter to monitor FPG
every day, 2 hours postprandial blood glucose and night blood glucose are optional, and blood
sugar is measured at any time if there are symptoms of hypoglycemia. The community doctor
adjusted the insulin dose according to the blood glucose level every day, and the patients
were followed up by telephone every week to collect the use of hypoglycemia, diet, exercise
and other hypoglycemic drugs, and record the time when the FPG reached the standard, the
total amount of insulin glargine, hypoglycemia and so on.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05219994 -
Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum
|
N/A | |
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Completed |
NCT02284893 -
Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone
|
Phase 3 | |
Completed |
NCT04274660 -
Evaluation of Diabetes and WELLbeing Programme
|
N/A | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Active, not recruiting |
NCT05566847 -
Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Completed |
NCT04965506 -
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
|
Phase 2 | |
Recruiting |
NCT06115265 -
Ketogenic Diet and Diabetes Demonstration Project
|
N/A | |
Active, not recruiting |
NCT03982381 -
SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
|
Phase 4 | |
Completed |
NCT04971317 -
The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages
|
N/A | |
Completed |
NCT04496154 -
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
|
N/A | |
Completed |
NCT04023539 -
Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
Completed |
NCT04097600 -
A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets
|
Phase 1 | |
Completed |
NCT05378282 -
Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
|
||
Active, not recruiting |
NCT06010004 -
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT03653091 -
Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes
|
N/A |